RES Group, Inc

RES Group Inc, an MIT spin-off and a pioneer in QSP (Quantitative Systems Pharmacology) modeling since 2001, is dedicated to accelerating and de-risking drug development. Utilizing mechanistic QSP modeling, we offer a range of services including First-in-Human (FIH) dose projections for IND applications, toxicity projections for regulatory submissions, and support for early-stage drug development. With a track record of successfully collaborating on over 100 new drug developments, we have earned the trust of biotech and pharmaceutical companies alike, as demonstrated by the following examples: Our MIDD (Model Informed Drug Development) approach for Takedas application for ultra-rare blood clotting disorder was...

Mechanistic quantitative systems pharmacology (qsp) modeling,midd (model informed drug development),fih (first-in-human) dosing,ind (investigational new drug) support,physiologically-based pharmacokinetic (pbpk) models,gene therapy models,immuno-oncology models,protein degrader models,lysosomal disorder models,hematological toxicity models,disease-progression models,and antibody-drug conjugates models

Res group, inc operates in the Biotechnology research industry.

Res group, inc's revenue is 11m - 100m

Res group, inc has 11 - 50 employees.